Median survival (median time taken to reach a consistent humane end-point based on tumor size) was 36 and 30.5 days after implantation for animals which received TR75-54.7 or TR75-89 anti-TNFR2 mAbs, compared to 22 days or 25 days for animals which received saline or hamster IgG control mAb respectively (p < 0.0001; Figure 5E). This evidence concerns the gene TNFRSF1B and neoplasm.